Ulrich Mrowietz

Summary

Affiliation: University of Kiel
Country: Germany

Publications

  1. ncbi Dimethylfumarate for psoriasis: more than a dietary curiosity
    Ulrich Mrowietz
    Department of Dermatology, University Clinic of Schleswig Holstein, Campus Kiel, 24105 Kiel, Germany
    Trends Mol Med 11:43-8. 2005
  2. ncbi Treatment of psoriasis with fumaric acid esters (Fumaderm)
    Ulrich Mrowietz
    Psoriasis Center, Department of Dermatology, Venereology and Allergy, University Clinic of Schleswig Holstein, Campus Kiel, Kiel, Germany
    J Dtsch Dermatol Ges 5:716-7. 2007
  3. doi Successful Treatment of Refractory Alopecia Areata Universalis and Psoriatic Arthritis, But Not of Plaque Psoriasis with Tofacitinib in a Young Woman
    Ulrich Mrowietz
    Psoriasis Center, Department of Dermatology, University Medical Center Schleswig Holstein, Campus Kiel, D 24105 Kiel, Germany
    Acta Derm Venereol . 2016
  4. doi Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)
    Ulrich Mrowietz
    Psoriasis Center, Department of Dermatology, University Medical Center Schleswig Holstein, Campus Kiel, Kiel, Germany Electronic address
    J Am Acad Dermatol 73:27-36.e1. 2015
  5. doi Systemic steroids in the treatment of psoriasis: what is fact, what is fiction?
    U Mrowietz
    Psoriasis Center at Department of Dermatology, University Medical Center Schleswig Holstein, Campus Kiel, Germany
    J Eur Acad Dermatol Venereol 27:1022-5. 2013
  6. ncbi Ten years of infliximab: its role in dermatology
    Ulrich Mrowietz
    Psoriasis Center, Dept of Dermatology, University Medical Center Schleswig Holstein, Campus Kiel, Germany
    Eur J Pharmacol 623:S10-6. 2009
  7. doi An assessment of adalimumab efficacy in three Phase III clinical trials using the European Consensus Programme criteria for psoriasis treatment goals
    U Mrowietz
    Psoriasis Center, Department of Dermatology, University Medical Center Schleswig Holstein, Campus Kiel, Kiel, Germany
    Br J Dermatol 168:374-80. 2013
  8. doi Implementing treatment goals for successful long-term management of psoriasis
    U Mrowietz
    Psoriasis Center, Department of Dermatology, University Medical Centre Schleswig Holstein, Campus Kiel, Germany
    J Eur Acad Dermatol Venereol 26:12-20. 2012
  9. pmc Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1beta, TNF-alpha and IL-6 in an in-vitro model of brain inflammation
    Henrik Wilms
    Department of Neurology, University of Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany
    J Neuroinflammation 7:30. 2010
  10. doi Strategies for improving the quality of care in psoriasis with the use of treatment goals--a report on an implementation meeting
    U Mrowietz
    Department of Dermatology, Psoriasis Center, University Medical Center Schleswig Holstein, Kiel, Germany
    J Eur Acad Dermatol Venereol 25:1-13. 2011

Detail Information

Publications90

  1. ncbi Dimethylfumarate for psoriasis: more than a dietary curiosity
    Ulrich Mrowietz
    Department of Dermatology, University Clinic of Schleswig Holstein, Campus Kiel, 24105 Kiel, Germany
    Trends Mol Med 11:43-8. 2005
    ..Recent evidence also shows that these effects are mediated through the interference of the intracellular redox system by DMF. Here, the mode of action of FAE and its clinical use for psoriasis will be discussed...
  2. ncbi Treatment of psoriasis with fumaric acid esters (Fumaderm)
    Ulrich Mrowietz
    Psoriasis Center, Department of Dermatology, Venereology and Allergy, University Clinic of Schleswig Holstein, Campus Kiel, Kiel, Germany
    J Dtsch Dermatol Ges 5:716-7. 2007
  3. doi Successful Treatment of Refractory Alopecia Areata Universalis and Psoriatic Arthritis, But Not of Plaque Psoriasis with Tofacitinib in a Young Woman
    Ulrich Mrowietz
    Psoriasis Center, Department of Dermatology, University Medical Center Schleswig Holstein, Campus Kiel, D 24105 Kiel, Germany
    Acta Derm Venereol . 2016
    ..is missing (Short communication)...
  4. doi Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)
    Ulrich Mrowietz
    Psoriasis Center, Department of Dermatology, University Medical Center Schleswig Holstein, Campus Kiel, Kiel, Germany Electronic address
    J Am Acad Dermatol 73:27-36.e1. 2015
    ..Secukinumab has demonstrated high, sustained efficacy in psoriasis to 52 weeks on a fixed-interval regimen...
  5. doi Systemic steroids in the treatment of psoriasis: what is fact, what is fiction?
    U Mrowietz
    Psoriasis Center at Department of Dermatology, University Medical Center Schleswig Holstein, Campus Kiel, Germany
    J Eur Acad Dermatol Venereol 27:1022-5. 2013
    ....
  6. ncbi Ten years of infliximab: its role in dermatology
    Ulrich Mrowietz
    Psoriasis Center, Dept of Dermatology, University Medical Center Schleswig Holstein, Campus Kiel, Germany
    Eur J Pharmacol 623:S10-6. 2009
    ..Today, dermatologists have collected a broad experience with infliximab treatment of psoriasis and they have thus advanced their clinical practice accordingly...
  7. doi An assessment of adalimumab efficacy in three Phase III clinical trials using the European Consensus Programme criteria for psoriasis treatment goals
    U Mrowietz
    Psoriasis Center, Department of Dermatology, University Medical Center Schleswig Holstein, Campus Kiel, Kiel, Germany
    Br J Dermatol 168:374-80. 2013
    ..The European Consensus Programme (ECP) established pan-European consensus definitions of psoriasis disease severity and treatment goals among 19 psoriasis experts from European nations...
  8. doi Implementing treatment goals for successful long-term management of psoriasis
    U Mrowietz
    Psoriasis Center, Department of Dermatology, University Medical Centre Schleswig Holstein, Campus Kiel, Germany
    J Eur Acad Dermatol Venereol 26:12-20. 2012
    ..This may, consequently, represent progress towards establishing a standard of care for psoriasis...
  9. pmc Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1beta, TNF-alpha and IL-6 in an in-vitro model of brain inflammation
    Henrik Wilms
    Department of Neurology, University of Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany
    J Neuroinflammation 7:30. 2010
    ..The purpose of this study was to use an established in vitro model of brain inflammation to determine if DMF modulates the release of neurotoxic molecules from microglia and astrocytes, thus inhibiting glial inflammation...
  10. doi Strategies for improving the quality of care in psoriasis with the use of treatment goals--a report on an implementation meeting
    U Mrowietz
    Department of Dermatology, Psoriasis Center, University Medical Center Schleswig Holstein, Kiel, Germany
    J Eur Acad Dermatol Venereol 25:1-13. 2011
    ..5 day educational meeting run by the Progressive Psoriasis Initiative to discuss how treatment goals in psoriasis might best be implemented in clinical practice. The meeting conclusions are presented here...
  11. doi Management of palmoplantar pustulosis: do we need to change?
    U Mrowietz
    Psoriasis Center at Department of Dermatology, University Medical Center Schleswig Holstein, Campus Kiel, Schittenhelmstr 7, 24105 Kiel, Germany
    Br J Dermatol 164:942-6. 2011
    ..The aim of this review is to challenge dermatologists to consider alternative management strategies for PPP and design clinical trials that will enable the development of useful therapeutic guidelines...
  12. ncbi An experimental ointment formulation of pimecrolimus is effective in psoriasis without occlusion
    Ulrich Mrowietz
    Department of Dermatology, University of Schleswig Holstein, Campus Kiel, Germany
    Acta Derm Venereol 83:351-3. 2003
    ..This is the first study reporting a significant therapeutic effect of pimecrolimus in an ointment formulation applied without occlusion to psoriatic plaques...
  13. pmc Definition of treatment goals for moderate to severe psoriasis: a European consensus
    U Mrowietz
    Department of Dermatology, University Medical Center Schleswig Holstein, Kiel, Germany
    Arch Dermatol Res 303:1-10. 2011
    ..It is planned to evaluate the implementation of these treatment goals in a subsequent programme involving patients and physicians...
  14. ncbi Keloid scarring: new treatments ahead
    Ulrich Mrowietz
    Department of Dermatology, University Medical Center Schleswig Holstein, Campus Kiel, Kiel, Germany
    Actas Dermosifiliogr 100:75-83. 2009
    ..This review provides an overview of the existing therapeutic options for keloid disease and summarizes upcoming future therapies with a special focus on blocking the transforming growth factor-beta pathway...
  15. ncbi [Therapy of psoriasis vulgaris with efalizumab]
    Ulrich Mrowietz
    Universitäts Hauklinik Kiel
    J Dtsch Dermatol Ges 4:511-2. 2006
  16. ncbi Leukocyte adhesion: a suitable target for anti-inflammatory drugs
    Ulrich Mrowietz
    Department of Dermatology, University of Kiel, Schittenhelmstr 7, 24105 Kiel, Germany
    Curr Pharm Des 12:2825-31. 2006
    ..This review aims to give an overview about the current knowledge of targeting adhesion molecules as a therapeutic strategy to treat inflammatory diseases...
  17. ncbi Survey regarding the status of senior physicians in German dermatology clinics
    Ulrich Mrowietz
    Department of Dermatology, Venerology and Allergology, University Clinic Schleswig Holstein, Campus Kiel, Germany
    J Dtsch Dermatol Ges 5:1002-7. 2007
    ..After the planned new pay schedule is instituted and restructuring of professorship in academic institutions is completed, the survey will be repeated...
  18. pmc The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients
    Ulrich Mrowietz
    Department of Dermatology, University of Kiel, Schittenhelmstrasse 7, 24105 Kiel, Germany
    Arch Dermatol Res 298:309-19. 2006
    ..Consequently, collaboration between physicians in different specialties is essential to ensuring that psoriasis treatment benefits the patient without exacerbating associated conditions...
  19. ncbi [Report of the 9th Psoriasis Specialty Congress, Bad Bentheim, 5 April 2003]
    U Mrowietz
    Abt Dermatologie, Venerologie und Allergologie, Universitatsklinikum Schleswig Holstein, Campus Kiel, Kiel
    Hautarzt 54:1131-4. 2003
  20. ncbi Psoriasis scales contain C5a as the predominant chemotaxin for monocyte-derived dendritic cells
    U Mrowietz
    Dept of Dermatology, University of Kiel, Schittenhelmstr 7, 24105 Kiel, Germany
    Exp Dermatol 10:238-45. 2001
    ..Our results provide evidence that C5a/C5adesarg although not specific for dendritic cells seems to be the major chemoattractant for these cells in lesional psoriasis skin...
  21. ncbi Advances in systemic therapy for psoriasis
    U Mrowietz
    Department of Dermatology, University of Kiel, Schittenhelmstrasse 7, 24105 Kiel, Germany
    Clin Exp Dermatol 26:362-7. 2001
    ....
  22. ncbi Macrolide immunosuppressants
    U Mrowietz
    Department of Dermatology, University of Kiel, Schittenhelmstr 7, 24105 Kiel, Germany
    Eur J Dermatol 9:346-51. 1999
    ..In this article the pharmacological aspects of macrolide immunosuppressants, their supposed mechanisms of action, pre-clinical and clinical experience are reviewed...
  23. ncbi The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion
    U Mrowietz
    Department of Dermatology, University of Kiel, Germany
    Br J Dermatol 139:992-6. 1998
    ..We conclude from our results that the new macrolactam SDZ ASM 981 (1%) is similar to clobetasol-17-propionate (0.05%) in plaque-type psoriasis when applied topically under occlusion for 2 weeks using the microplaque assay...
  24. pmc Psoriasis--new insights into pathogenesis and treatment
    Ulrich Mrowietz
    Psoriasis Zentrum, Abteilung Dermatologie, Venerologie und Allergologie, Universitatsklinikum Schleswig Holstein, Campus Kiel, Schittenhelmstr 7, 24105 Kiel, Germany
    Dtsch Arztebl Int 106:11-8, quiz 19. 2009
    ..Psoriasis is one of the most prevalent chronic inflammatory diseases, affecting approximately 2 million people in Germany...
  25. ncbi Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. German Multicentre Study
    U Mrowietz
    Department of Dermatology, University of Kiel, Germany
    Br J Dermatol 138:456-60. 1998
    ..Transient eosinophilia seems to be a characteristic feature of FAE therapy, while lymphocytopenia is usually mild. Adverse effects are dose-related and consist mainly of gastrointestinal complaints and flushing...
  26. ncbi Treatment targeted to cell surface epitopes
    U Mrowietz
    Department of Dermatology, University of Kiel, Germany
    Clin Exp Dermatol 27:591-6. 2002
    ..Clinical as well as experimental data obtained with the various compounds employed are discussed with regard to clinical efficacy, safety and tolerability...
  27. ncbi [Psoriasis therapy with biologicals]
    U Mrowietz
    Abt Dermatologie, Venerologie und Allergologie, Universitatsklinikum Schleswig Holstein, Campus Kiel
    Hautarzt 54:224-9. 2003
    ..Blockade of adhesion molecules to prevent extravasation of inflammatory cells is a new strategy under development. This article reviews about the current knowledge of psoriasis therapy with biologicals...
  28. doi Effective treatment and improvement of quality of life in patients with scalp psoriasis by topical use of calcipotriol/betamethasone (Xamiol®-gel): results
    Ulrich Mrowietz
    Psoriasis Center, Department of Dermatology, Venereology and Allergy, University Medical Center Schleswig Holstein, Campus Kiel, Germany
    J Dtsch Dermatol Ges 9:825-31. 2011
    ..Quality of life of patients with scalp psoriasis is greatly impaired due to itch and scaling. To control the disease long-term therapy is necessary and treatment success is greatly dependent on compliance...
  29. ncbi [Therapy of psoriasis-arthritis and psoriasis vulgaris with infliximab]
    Ulrich Mrowietz
    Universitäts Hauklinik Kiel, D 24105 Kiel
    J Dtsch Dermatol Ges 4:444-7. 2006
  30. doi S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update
    Alexander Nast
    Division of Evidence Based Medicine dEBM, Klinik fur Dermatologie, Venerologie und Allergologie, Charite Universitatsmedizin Berlin, Germany
    J Dtsch Dermatol Ges 10:S1-95. 2012
    ..The therapeutic recommendations were developed based on the results of a systematic literature search and were finalized during a consensus meeting using structured consensus methods (nominal group process)...
  31. pmc Genome-wide meta-analysis of psoriatic arthritis identifies susceptibility locus at REL
    Eva Ellinghaus
    Institute of Clinical Molecular Biology, Christian Albrechts University Kiel, Kiel, Germany
    J Invest Dermatol 132:1133-40. 2012
    ..We hypothesize that c-Rel, as a member of the Rel/NF-κB family, is associated with PsA in the context of disease pathways that involve other identified PsA and PsV susceptibility genes including TNIP1, TNFAIP3, and NFκBIA...
  32. doi Therapy of psoriasis in childhood and adolescence - a German expert consensus
    Michael Sticherling
    Department of Dermatology, University Hospital Erlangen, Germany
    J Dtsch Dermatol Ges 9:815-23. 2011
    ..In any case the therapy has to be individually planned and decided together with the patients and their parents to gain maximal safety, comfort and success...
  33. ncbi Dimethylfumarate is a potent inducer of apoptosis in human T cells
    Felix Treumer
    Department of Dermatology, University of Kiel, Kiel, Germany
    J Invest Dermatol 121:1383-8. 2003
    ..The data provide evidence that the effect of FAE treatment of psoriasis may at least in part be due to induction of apoptosis in activated T cells...
  34. ncbi A molecule solves psoriasis? Systemic therapies for psoriasis inducing interleukin 4 and Th2 responses
    Kamran Ghoreschi
    Department of Dermatology, University of Tubingen, Liebermeisterstrasse 25, 72076 Tubingen, Germany
    J Mol Med (Berl) 81:471-80. 2003
    ..Further studies are needed to determine the central role of IL-4 in the control of Th1-induced autoimmune disease, namely psoriasis...
  35. doi Recommendations for the long-term treatment of psoriasis with infliximab: a dermatology expert group consensus
    Kristian Reich
    Department of Dermatology, Dermatologikum Hamburg, Hamburg, Germany
    Dermatology 217:268-75. 2008
    ..To date, there is little or no information about the long-term management in clinical trials or guidelines...
  36. pmc Triptolide in the treatment of psoriasis and other immune-mediated inflammatory diseases
    Rui Han
    Department of Dermatology, University Medical Center Schleswig Holstein, Campus Kiel, Germany
    Br J Clin Pharmacol 74:424-36. 2012
    ..In this review we summarize the published knowledge regarding clinical use, pharmacokinetics and the possible mode of action of triptolide in the treatment of inflammatory diseases with a particular focus on psoriasis...
  37. ncbi The use of infliximab in dermatology
    Silja Rott
    Department of Dermatology, Venereology and Allergy University of Schleswig Holstein, Campus Kiel, Kiel, Germany
    J Dtsch Dermatol Ges 5:655-60. 2007
    ..Nevertheless, infliximab is not approved for these indications at the moment and has to be considered as off-label use...
  38. doi National and multinational guidelines in Europe: results from an online survey on awareness of different national and European psoriasis guidelines
    Alexander Nast
    Division of Evidence Based Medicine, Klinik fur Dermatologie, Venerologie und Allergologie, Charite Universitatsmedizin Berlin, Germany
    Arch Dermatol Res 305:637-43. 2013
    ..National guidelines can reach almost complete awareness within their respective countries. The original publication is still the most important dissemination tool for guidelines...
  39. doi Adipokines and psoriasis
    Sascha Gerdes
    Psoriasis Center at the Department of Dermatology, University Medical Center Schleswig Holstein, Campus Kiel, Kiel, Germany
    Exp Dermatol 20:81-7. 2011
    ..Adipokines could serve as a missing link in the causal relationship between psoriasis and comorbidities and may provide a biomarker for disease severity, risk of comorbidities and treatment success...
  40. doi Enhanced expression and secretion of antimicrobial peptides in atopic dermatitis and after superficial skin injury
    Jurgen Harder
    Department of Dermatology, Allergology, and Venerology, University Hospital Schleswig Holstein, Campus Kiel, Kiel, Germany
    J Invest Dermatol 130:1355-64. 2010
    ..Thus, a disturbed skin barrier may trigger AMP induction in AD and psoriasis. The functional role of AMP in AD, especially with regard to the control of S. aureus colonization, needs further analysis...
  41. ncbi Inhibition of dendritic cell differentiation by fumaric acid esters
    K Zhu
    Department of Dermatology, University of Kiel, Schittenhelmstr. 7, 24105 Kiel, Germany
    J Invest Dermatol 116:203-8. 2001
    ....
  42. ncbi Vitamin D(3) and analogues modulate the expression of CSF-1 and its receptor in human dendritic cells
    Kejian Zhu
    Department of Dermatology, University of Kiel, Kiel, Germany
    Biochem Biophys Res Commun 297:1211-7. 2002
    ....
  43. doi Bacterial soft tissue infection in psoriasis despite induction of epidermal antimicrobial peptides
    Kirsten Steinz
    Department of Dermatology, University Hospital Schleswig Holstein, Kiel, Germany
    Exp Dermatol 23:862-4. 2014
    ..Therefore, other factors, for example deep penetrating injuries bypassing the keratinocyte innate defense system, must have caused the soft tissue infection. ..
  44. doi Detection of fumarate-glutathione adducts in the portal vein blood of rats: evidence for rapid dimethylfumarate metabolism
    Stefan Dibbert
    Psoriasis Center at the Department of Dermatology, University Medical Center Schleswig Holstein, Campus Kiel, Kiel, Germany
    Arch Dermatol Res 305:447-51. 2013
    ....
  45. ncbi Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris
    Alexander Nast
    Division of Evidence Based Medicine dEBM, Klinik fur Dermatologie, Venerologie und Allergologie, Charite Universitatsmedizin Berlin, Germany
    J Dtsch Dermatol Ges 5:1-119. 2007
    ..The therapeutic recommendations were developed by an expert group and finalized during interdisciplinary consensus conferences...
  46. pmc Recent developments in the use of biologics in psoriasis and autoimmune disorders. The role of autoantibodies
    Silja Rott
    Department of Dermatology, University of Kiel, 24105 Kiel, Germany
    BMJ 330:716-20. 2005
  47. ncbi Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. The German Fumaric Acid Ester Consensus Conference
    U Mrowietz
    Department of Dermatology, University of Kiel, Schittenhelmstr 7, 24105 Kiel, Germany
    Br J Dermatol 141:424-9. 1999
    ..This article reviews the experimental and clinical information on FAEs in psoriasis and provides guidelines for the clinical use of FAEs derived from a consensus meeting of leading experts...
  48. ncbi [Classical topical therapy of psoriasis]
    S Gerdes
    Psoriasis Zentrum an der Klinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Schleswig Holstein Campus Kiel, Schittenhelmstrasse 7, 24105, Kiel
    Hautarzt 57:666-71. 2006
    ..Through the continuous development of these compounds, a better risk-benefit profile has been achieved. Corticosteroids are the most frequently employed topical agent for psoriasis treatment worldwide...
  49. doi The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature
    S Domm
    Psoriasis Center at the Department of Dermatology, University Medical Center Schleswig Holstein, Campus Kiel, Schittenhelmstr 7, 24105 Kiel, Germany
    Br J Dermatol 159:1217-28. 2008
    ..This short review will give an overview of the most recent data available on the effects of anti-TNF-alpha therapy on viral infections with a particular focus on patient management and screening recommendations...
  50. doi Serum mast cell tryptase is not a useful marker for disease severity in psoriasis or atopic dermatitis
    S Gerdes
    Psoriasis Center at the Department of Dermatology, University Clinic of Schleswig Holstein, Campus Kiel, 24105 Kiel, Germany
    Br J Dermatol 160:736-40. 2009
    ..As mast cells play an important role in the pathogenesis of early psoriasis and AD, tryptase, a major compound of mast cell granules that is released upon activation, could in principle serve as such a marker...
  51. doi Comedication related to comorbidities: a study in 1203 hospitalized patients with severe psoriasis
    S Gerdes
    Psoriasis Center at the Department of Dermatology, University Clinic of Schleswig Holstein, Campus Kiel, 24105 Kiel, Germany
    Br J Dermatol 159:1116-23. 2008
    ..The treatments for these diseases may interfere with the course and the treatment of psoriasis. Little is known on the general drug intake of patients with psoriasis...
  52. ncbi Dimethylfumarate inhibits nuclear binding of nuclear factor kappaB but not of nuclear factor of activated T cells and CCAAT/enhancer binding protein beta in activated human T cells
    S Gerdes
    Psoriasis Center at the Department of Dermatology, University of Kiel, Schittenhelmstr 7, Kiel, Germany
    Br J Dermatol 156:838-42. 2007
    ..The influence of FAEs on the expression of nuclear transcription factors in T cells has not yet been investigated...
  53. ncbi Development of a new method of analysing chemotactic deactivation of human neutrophil granulocytes
    O Bock
    Department of Dermatology, University of Kiel, Schittenhelmstr 7, D 24105, Kiel, Germany
    J Biochem Biophys Methods 48:257-68. 2001
    ..This new chamber can be very helpful in detecting unknown chemotactic stimuli, which are not detectable by, for example, antibodies...
  54. ncbi Expression of dipeptidyl-peptidase IV (CD26) on CD8+ T cells is significantly decreased in patients with psoriasis vulgaris and atopic dermatitis
    O Bock
    Department of Dermatology, Christian Albrechts University of Kiel, Schittenhelmstrasse 7, D 24105 Kiel, Germany
    Exp Dermatol 10:414-9. 2001
    ..Since CD26 can be regarded as an anti-inflammatory principle the decreased expression in psoriasis and atopic dermatitis patients may lead to a dysbalance in favour of pro-inflammatory mediators in both clinical conditions...
  55. ncbi [Keloids. A fibroproliferative disorder of unknown etiology]
    O Bock
    Universitäts Hautklinik Kiel, Abteilung Dermatologie, Venerologie und Allergologie, Kiel, Germany
    Hautarzt 53:515-23. 2002
    ..In addition topical treatment with extracts of onions, occlusive silicone sheets and pressure improves the clinical appearance of keloids...
  56. ncbi [Skin blackish hyperpigmentation in 3 patients]
    O Bock
    Universitäts Hautklinik Kiel Schittenhelmstrasse 7, 24105 Kiel
    Hautarzt 53:416-20. 2002
  57. doi Impact of comorbidities on the management of psoriasis
    S Gerdes
    Psoriasis Center at the Department of Dermatology, University Medical Center Schleswig Holstein, Campus Kiel, Kiel, Germany
    Curr Probl Dermatol 38:21-36. 2009
    ..This article will summarize the current knowledge on comorbidities in psoriasis and their impact on patient management...
  58. doi Systemic treatment with fumaric acid esters in six paediatric patients with psoriasis in a psoriasis centre
    Kirsten Steinz
    Psoriasis Centre at the Department of Dermatology, University Medical Centre Schleswig Holstein, Campus Kiel, Kiel, Germany
    Dermatology 229:199-204. 2014
    ..Psoriasis is one of the most common inflammatory skin disorders. There are only limited data on systemic treatment in children...
  59. doi Leptin, adiponectin, visfatin and retinol-binding protein-4 - mediators of comorbidities in patients with psoriasis?
    Sascha Gerdes
    Psoriasis Center at the Department of Dermatology, University Medical Center Schleswig Holstein, Campus Kiel, Kiel, Germany
    Exp Dermatol 21:43-7. 2012
    ....
  60. doi Combination therapy in the treatment of psoriasis
    Silja Domm
    Psoriasis Center, Department of Dermatology, Venerology and Allergology, University Hospital of Schleswig Holstein, Campus Kiel, Germany
    J Dtsch Dermatol Ges 9:94-8. 2011
    ..This provides a quick overview of available options...
  61. doi Psoriasis of the tongue
    Guido C Lier
    Department of Oral and Maxillofacial Surgery, University of Kiel, Germany
    J Craniomaxillofac Surg 37:51-3. 2009
    ..Psoriasis is a common, chronic dermatologic disease. Cases affecting the oral mucous membranes are rarely reported in the international literature, in particular tongue lesions are hardly ever documented...
  62. doi Fumaric acid esters
    Martin Rostami Yazdi
    Psoriasis Center at the Department of Dermatology, University of Kiel, Kiel, Germany
    Clin Dermatol 26:522-6. 2008
    ..For these data, the role of DMF as a modulator of intracellular glutathione plays an important role...
  63. ncbi European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey
    L Dubertret
    Department of Dermatology, Venereology and Allergology, University Clinic Schleswig Holstein, Kiel, Germany
    Br J Dermatol 155:729-36. 2006
    ..EUROPSO (European Federation of Psoriasis Patient Associations) undertook a Europe-wide survey examining quality of life and patients' perspectives on treatment and their disease...
  64. ncbi Follicular rash during therapy with erlotinib (Tarceva)
    Sascha Gerdes
    Clinic for Dermatology, Venerology and Allergology, University Clinic Schleswig Holstein, Campus Kiel, Kiel, Germany
    J Dtsch Dermatol Ges 4:855-7. 2006
    ..The severity of the skin rash seems to be correlated to clinical response and should be a motivating factor to continue therapy. We report a case of a patient who developed a follicular rash during therapy with erlotinib...
  65. pmc Genome-wide comparative analysis of atopic dermatitis and psoriasis gives insight into opposing genetic mechanisms
    Hansjörg Baurecht
    Department of Dermatology, Allergology, and Venereology, University Hospital Schleswig Holstein, Campus Kiel, 24105 Kiel, Germany
    Am J Hum Genet 96:104-20. 2015
    ..The approach is likely to be applicable to the investigation of the genetic basis of other complex traits with overlapping and distinct clinical features. ..
  66. doi Wnt5a: a potential factor linking psoriasis to metabolic complications
    Sascha Gerdes
    Psoriasis Center at the Department of Dermatology, University Medical Center Schleswig Holstein, Campus Kiel, Kiel, Germany
    Exp Dermatol 23:438-40. 2014
    ..177 ng/ml; SD 0.14) compared with obese healthy controls (0.011 ng/ml; SD 0.03; P ≤ 0.001). Therefore, we suggest that in psoriasis, an increase in wnt5a may contribute to the development of metabolic comorbidity...
  67. doi Cardiovascular biomarkers in patients with psoriasis
    Sascha Gerdes
    Psoriasis Center at the Department of Dermatology, University Medical Center Schleswig Holstein, Campus Kiel, Kiel, Germany
    Exp Dermatol 23:322-5. 2014
    ..This knowledge may be useful in the management of high-need patients with psoriasis. ..
  68. doi Pharmacokinetics of anti-psoriatic fumaric acid esters in psoriasis patients
    Martin Rostami-Yazdi
    Psoriasis Center at the Department of Dermatology, University Medical Center Schleswig Holstein, Kiel, Germany
    Arch Dermatol Res 302:531-8. 2010
    ..63. The data of this study provide evidence that DMF is most likely absorbed out of the duodenum into the presystemic circulation and is not completely hydrolysed to MMF before uptake as assumed by others...
  69. doi The Schnitzler syndrome: chronic urticaria and monoclonal gammopathy--an autoinflammatory syndrome?
    Elisabeth Eiling
    Department of Dermatology, Venereology and Allergy, University Hospital Schleswig Holstein, Campus Kiel, Germany
    J Dtsch Dermatol Ges 6:626-31. 2008
    ....
  70. doi Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab
    Viola Harde
    Department of Dermatology, Allergy and Venereology, University Clinic Schleswig Holstein, Campus Kiel, Schittenhelmstrasse 7, Kiel, Germany
    J Dtsch Dermatol Ges 7:139-41. 2009
    ..Here we report a case of a patient with severe recalcitrant hidradenitis suppurativa successfully treated with adalimumab...
  71. ncbi Decreased expression of inhibitory SMAD6 and SMAD7 in keloid scarring
    Haiyan Yu
    Department of Dermatology, University of Kiel, Kiel, Germany
    J Plast Reconstr Aesthet Surg 59:221-9. 2006
    ..This could explain why TGFbeta signaling is not terminated in keloids leading to overexpression of extracellularmatrix in keloids. These data support a possible role of SMAD6 and 7 in the pathogenesis of keloids...
  72. pmc The chemokine RANTES is secreted by human melanoma cells and is associated with enhanced tumour formation in nude mice
    U Mrowietz
    Department of Dermatology, Univeristy of Kiel, Germany
    Br J Cancer 79:1025-31. 1999
    ..However, transplantation experiments in nude mice suggest that effects of RANTES may also benefit tumour progression. Further studies are needed to dissect the underlying mechanisms...
  73. pmc Metastatic potential of human melanoma cells in nude mice--characterisation of phenotype, cytokine secretion and tumour-associated antigens
    D Schadendorf
    Virchow Clinic, Department of Dermatology, Humboldt University of Berlin, Germany
    Br J Cancer 74:194-9. 1996
    ....
  74. doi Smoking and alcohol intake in severely affected patients with psoriasis in Germany
    S Gerdes
    Psoriasis Center at the Department of Dermatology, University Medical Center Schleswig Holstein, Kiel, Germany sgerdes dermatology uni kiel de
    Dermatology 220:38-43. 2010
    ..Smoking and alcohol may contribute as triggering factors for psoriasis and are substantial for managing severely affected psoriasis patients...
  75. doi Dimethyl- and monomethylfumarate regulate indolamine 2,3-dioxygenase (IDO) activity in human immune cells
    Sevgi Eminel
    Psoriasis Center, Dept of Dermatology, University Medical Center Schleswig Holstein, Campus Kiel, Germany
    Exp Dermatol . 2016
    ..This article is protected by copyright. All rights reserved...
  76. doi Psoriasis: to treat or to manage?
    Ulrich Mrowietz
    Psoriasis Center, Department of Dermatology, University Medical Center Schleswig Holstein, Campus Kiel, Germany
    Exp Dermatol 23:705-9. 2014
    ..Finally, outcome tools should specifically be tailored for psoriasis to evaluate disease-related items as well as the benefit of management from the patient's perspective. ..
  77. ncbi Localized panniculitis and subsequent lipoatrophy with subcutaneous glatiramer acetate (Copaxone) injection for the treatment of multiple sclerosis
    Noemi Soós
    Department of Dermatology, University of Kiel, Kiel, Germany
    Am J Clin Dermatol 5:357-9. 2004
    ....
  78. pmc Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2
    Eva Ellinghaus
    Institute of Clinical Molecular Biology, Christian Albrechts University, Kiel, Germany
    Nat Genet 42:991-5. 2010
    ..TRAF3IP2 encodes a protein involved in IL-17 signaling and which interacts with members of the Rel/NF-κB transcription factor family...
  79. ncbi Treatment goals in psoriasis
    Kristian Reich
    Dermatologikum Hamburg, Germany
    J Dtsch Dermatol Ges 5:566-74. 2007
    ..Patients should carefully be monitored for the presence of psoriatic arthritis and comorbidities because these may need to be integrated in the planning of treatment goals on an interdisciplinary basis...
  80. ncbi Calcitriol ointment and clobetasol propionate cream: a new regimen for the treatment of plaque psoriasis
    Morad Lahfa
    Hopital Saint Louis, 1 avenue Claude Vellefaux, 25015 Paris, France
    Eur J Dermatol 13:261-5. 2003
    ....
  81. ncbi [S3-Guidelines for the therapy of psoriasis vulgaris]
    Alexander Nast
    Division of Evidence Based Medicine dEBM, Klinik fur Dermatologie, Venerologie und Allergologie, Charite Universitatsmedizin Berlin
    J Dtsch Dermatol Ges 4:S1-126. 2006
  82. ncbi [Therapy of atopic eczema with calcineurin inhibitors]
    Thomas A Luger
    Hautklinik, Universitätsklinikkum Münster, Deutschland
    J Dtsch Dermatol Ges 3:385-91. 2005
  83. ncbi Reactivity of dimethyl fumarate and methylhydrogen fumarate towards glutathione and N-acetyl-L-cysteine--preparation of S-substituted thiosuccinic acid esters
    Thomas J Schmidt
    Westfalische Wilhelms Universitat, Institut für Pharmazeutische Biologie und Phytochemie IPBP, Hittorfstrasse 56, D 48149 Munster, Germany
    Bioorg Med Chem 15:333-42. 2007
    ..On the other hand, MHF, due to its slow reaction with GSH, may have higher chances than DMF to react with more essential thiol groups in macromolecules...
  84. doi A study examining inter-rater and intrarater reliability of a novel instrument for assessment of psoriasis: the Copenhagen Psoriasis Severity Index
    J Berth-Jones
    Department of Dermatology, University Hospitals Coventry and Warwickshire NHS Trust, Coventry CV2 2DX, UK
    Br J Dermatol 159:407-12. 2008
    ....
  85. ncbi Increased expression of Wnt5a in psoriatic plaques
    Joachim Reischl
    Schering AG Berlin, Global Pharmacogenomics, Biomarker Development and Non Clinical Statistics, Berlin, Germany
    J Invest Dermatol 127:163-9. 2007
    ..We conclude that Wnt5a and other Wnt pathway genes are differentially expressed in psoriatic plaques. Their functional contribution to the pathophysiology of psoriasis needs to be elaborated...
  86. ncbi Towards a new horizon
    Ulrich Mrowietz
    Arch Dermatol Res 300:1-2. 2008
  87. ncbi Quality of life of patients with keloid and hypertrophic scarring
    Oliver Bock
    Primary Health Care Center, Hälsan 2, Fabriksgatan 17, 55 185, Jonkoping, Sweden
    Arch Dermatol Res 297:433-8. 2006
    ..This study demonstrates for the first time an impairment of quality of life in a large group of patients with keloid and hypertrophic scarring...
  88. ncbi Enhancement of antibacterial superoxide-anion generation in human monocytes by fumaric acid esters
    Kejian Zhu
    Department of Dermatology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, 3 East Qing Chun Road, Hangzhou 310009, People s Republic of China
    Arch Dermatol Res 297:170-6. 2005
    ..Expression of mannose receptors on monocytes was not regulated by DMF or MHF. Our data provide evidence that DMF and MHF do not alter the production of superoxide anions as an important mechanism of innate defense against microorganisms...
  89. ncbi [Therapy of psoriasis vulgaris and psoriatic arthritis with etanercept]
    Ulrich Mrowietz
    J Dtsch Dermatol Ges 3:470-2. 2005
  90. ncbi Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease
    Kamran Ghoreschi
    Department of Dermatology and Allergology, Ludwig Maximilians University Munich, Munich, Germany
    Nat Med 9:40-6. 2003
    ..Thus, IL-4 therapy can induce Th2 differentiation in human CD4+ T cells and has promise as a potential treatment for psoriasis, a prototypic Th1-associated autoimmune disease...